APA (7th ed.) Citation

F, P., S, B., V, D., JF, E., L, P., C, F., . . . F, J. (2017). Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: An open-label, multicentre, single-arm, phase 2 trial from the LYSA group. The Lancet. Haematology, 4(1), e46. https://doi.org/10.1016/S2352-3026(16)30171-5

Chicago Style (17th ed.) Citation

F, Peyrade, et al. "Combination of Ofatumumab and Reduced-dose CHOP for Diffuse Large B-cell Lymphomas in Patients Aged 80 Years or Older: An Open-label, Multicentre, Single-arm, Phase 2 Trial from the LYSA Group." The Lancet. Haematology 4, no. 1 (2017): e46. https://doi.org/10.1016/S2352-3026(16)30171-5.

MLA (9th ed.) Citation

F, Peyrade, et al. "Combination of Ofatumumab and Reduced-dose CHOP for Diffuse Large B-cell Lymphomas in Patients Aged 80 Years or Older: An Open-label, Multicentre, Single-arm, Phase 2 Trial from the LYSA Group." The Lancet. Haematology, vol. 4, no. 1, 2017, p. e46, https://doi.org/10.1016/S2352-3026(16)30171-5.